News

Video

The APAC Recap: Dyslipidemia at CAPP Live 2024 with Viet Le, DMSc, PA-C

Key Takeaways

  • The 2022 AHA/ACC consensus emphasizes reclassifying high-risk ASCVD patients and targeting LDL-C levels of ≤55 mg/dL using non-statin therapies.
  • Pitavastatin is highlighted as an effective alternative for statin-intolerant patients, reducing LDL-C levels by 30–49% when combined with ezetimibe or bempedoic acid.
SHOW MORE

Past APAC President Viet Le shares insights from CAPP 2024 on managing high-risk ASCVD, new non-statin therapies, and options for statin-intolerant patients.

In this episode of The APAC Recap, Laura Ross, PA-C, president of the Academy of Physician Associates in Cardiology (APAC), welcomed Viet Le, DMSc, PA-C, immediate past president of APAC, to recap his presentations at the inaugural Cardiology Advanced Practice Providers (CAPP) Live 2024 conference. Le, a preventive cardiology PA at Intermountain Health, shares insights from his sessions covering lipid management, metabolic dysfunction, liver disease, and chest pain guidelines, focusing particularly on lipid strategies for the APAC audience.

One major point he discussed is the 2022 American Heart Association (AHA)/American College of Cardiology (ACC) expert consensus pathway for non-statin therapies, emphasizing the importance of reclassifying high-risk patients with atherosclerotic cardiovascular disease (ASCVD). Le advised cardiology PAs and NPs to recognize those with very high-risk ASCVD profiles and to aim for an LDL-cholesterol target (LDL-C) of ≤55 mg/dL, beyond standard statin therapy, using options like ezetimibe, bempedoic acid, and PCSK9 inhibitors.

A highlight from Le’s presentation was his advice on managing statin intolerance, a common referral reason in preventive cardiology. He discussed the benefits of pitavastatin, a lesser-known statin with a high success rate in patients who experience myalgia on other statins. Le explained that pitavastatin’s unique formulation, originating from research by a Japanese pharmaceutical company, makes it an effective alternative for lipid lowering in statin-intolerant patients, reducing LDL-C levels by 30–49% when used at 2 or 4 mg, especially when combined with ezetimibe or bempedoic acid.

To conclude, Le reviewed the 2022 expert consensus on non-statin therapies and discussed the importance of risk-enhancing factors, particularly in women with conditions like preeclampsia or premature menopause, which are often overlooked yet critical in risk assessment. Their discussion emphasizes practical, evidence-based approaches to lipid management, equipping cardiology providers to optimize patient care.

All episodes of The APAC Recap will be available on HCPLive.com and on our YouTube channel!

Related Videos
Highlighting the Danger of SCI Progression during iTTP Remission, with Shruti Chaturvedi, MBSS, MS
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Jörn Schattenberg, MD | Credit: Novo Nordisk
© 2024 MJH Life Sciences

All rights reserved.